Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 5 minute read Pharma Industry News AVEO Oncology begins Phase 1b/2 ficlatuzumab trial in elderly AML patients via Blood Cancer United collaboration AVEO Oncology has begun a Beat AML trial for ficlatuzumab in elderly AML patients. See how this could reshape front-line cancer care for high-risk groups. bySrinathJanuary 16, 2026